Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

1 of 0 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment reporting

Analytics

Phase 3

1(33.3%)

Phase 4

1(33.3%)

Phase 2

1(33.3%)

3Total

Phase 3(1)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials

NCT05170256Phase 2Unknown

Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

Role: co_sponsor

SYFd13707b2ef764c26a3a85ae6e776a4b4Phase 3Unknown

Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK)

Role: lead

SYFdeb9146f84cc419eb710348bbb677a1bPhase 4Recruiting

Botox Treatment for Patients with Hidradenitis Suppurativa: A Within-Person, Randomized, Double-blind, Controlled Study

Role: co_sponsor

All 3 trials loaded